Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EpCAM-directed CAR T cells
- Development stage
- Unknown
- Lead developer
- Ludwig Maximilian University of Munich
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intraperitoneal, Intratumoral, Intravenous
01
Overview
EpCAM-directed CAR T cells are an experimental, preclinical cell therapy consisting of T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting epithelial cell adhesion molecule (EpCAM), a tumor-associated antigen highly expressed on epithelial-derived tumors and metastases. Developed by researchers at Ludwig-Maximilians-University Munich (LMU Munich), this adoptive T-cell immunotherapy has been investigated in preclinical models of lung cancer brain metastases. In syngeneic mouse models, local (intraparenchymal) administration of these CAR T cells demonstrated significant intratumoral accumulation, reduced tumor growth, and prolonged survival, whereas systemic (intravenous) administration showed limited efficacy. To overcome the immunosuppressive tumor microenvironment and enhance CAR T-cell persistence, researchers have explored combination strategies, including CSF1R inhibition to deplete tumor-associated macrophages and microglia (TAM/M) or co-administration with anti-angiogenic agents (anti-VEGF-A/VEGF-R2).
- Other names
- EpCAM CAR-T cellsEpCAM-directed CAR T-cellsanti-EpCAM CAR-T cells
Beyond the preview
Go deeper on EpCAM-directed CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpCAM-directed CAR T cells.